Last reviewed · How we verify
sIPV+DTaP+MMR
This combination vaccine provides immunization against poliomyelitis, diphtheria, tetanus, pertussis, measles, mumps, and rubella through inactivated viral and bacterial antigens.
This combination vaccine provides immunization against poliomyelitis, diphtheria, tetanus, pertussis, measles, mumps, and rubella through inactivated viral and bacterial antigens. Used for Prevention of poliomyelitis, Prevention of diphtheria, Prevention of tetanus.
At a glance
| Generic name | sIPV+DTaP+MMR |
|---|---|
| Sponsor | China National Biotec Group Company Limited |
| Drug class | Combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease Prevention |
| Phase | FDA-approved |
Mechanism of action
sIPV+DTaP+MMR is a multi-component vaccine combining inactivated poliovirus vaccine (sIPV), diphtheria-tetanus-acellular pertussis vaccine (DTaP), and measles-mumps-rubella vaccine (MMR). It stimulates humoral and cellular immune responses against these pathogens, inducing production of protective antibodies and memory B/T cells to prevent infection.
Approved indications
- Prevention of poliomyelitis
- Prevention of diphtheria
- Prevention of tetanus
- Prevention of pertussis
- Prevention of measles
- Prevention of mumps
- Prevention of rubella
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Rash
- Myalgia
- Headache
Key clinical trials
- Study of Concomitant Administration of the sIPV and DTaP or MMR (PHASE4)
- Immunogenicity of After Primary Immunization and Booster Immunization of sIPV
- A Safety Study of Sabin Inactivated Poliovirus Vaccine in Infants (PHASE4)
- Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sIPV+DTaP+MMR CI brief — competitive landscape report
- sIPV+DTaP+MMR updates RSS · CI watch RSS
- China National Biotec Group Company Limited portfolio CI